A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines (SPOTLIGHT)

A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

This is an open-label, single ascending dose Phase 1b/2a trial to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with Cold Urticaria (ColdU) or Symptomatic Dermographism (SD), who remain symptomatic despite treatment with H1 antihistamines. The trial will explore three ascending dose levels which will be tested in three sequential cohorts.

Study Overview

• Status: Terminated
• Conditions: Chronic Inducible Urticaria
• Intervention / Treatment: Drug: Briquilimab

• Study Type: Interventional
• Enrollment (Actual): 27
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 12203
    • Charité - University Clinic Berlin
  • Dresden, Germany, 01307
    • University Hospital Dresden
  • Lübeck, Germany, 23538
    • University Clinic Schleswig-Holstein
  • Marburg, Germany, 35043
    • University of Marburg
  • Münster, Germany, 48149
    • University of Munster

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Written informed consent obtained from potential participants capable of providing informed consent, after the nature of the trial has been fully explained and before performing any trial related assessments
2. Males and females, ≥18 years old

3. Diagnosis of ColdU or SD despite the use of H1-antihistamines as defined by all of the following:

   • Diagnosis of ColdU or SD for ≥ 3 months, symptoms must comprise both wheal and itch or painful sensation
   • Presence of itch and hives for ≥ 6 consecutive weeks at any time prior to Screening despite current use of H1-antihistamines (as reported by the participant)
   • ColdU participants must have a positive cold stimulation tests above 4ºC using TempTest® (wheal and itch or painful sensation) on site during Screening to be eligible
   • SD participants must have a positive FricTests® with ≥ 3 pins (wheal and itch) on site during Screening to be eligible
4. Use of H1-antihistamines on stable dose up to four-fold of the approved dose for at least 4 weeks prior to the Screening visit and not expected to change during first 12 weeks of the trial.
5. Participants with chronic spontaneous urticaria (CSU) are eligible if they present with symptoms consistent with ColdU or SD and ColdU or SD is the dominant type of chronic urticaria.

6. Blood counts at Screening with:

   • Hemoglobin: ≥ 11 g/dl
   • Platelets: ≥ 100,000/mm3
   • Leucocytes: ≥ 3,000/mm3
   • Neutrophils: ≥ 2,000/mm3
7. Willing and able to participate and adhere to the trial visits schedule.

Exclusion Criteria:

1. Women who are pregnant or nursing or intend to become pregnant during the course of the trial
2. Participants weighing less than 40 kg or more than 125 kg at Screening
3. Dominant comorbid chronic urticaria with a clearly defined predominant or sole trigger (chronic inducible urticaria) other than ColdU or SD, including, heat-, solar-, pressure-,delayed pressure-, aquagenic-, cholinergic-, or contact urticaria as well as variants of cold induced urticaria or familial cold autoimmune syndrome except CSU (see inclusion criterion #5)
4. Other active diseases with possible symptoms of urticaria, wheals or angioedema, including urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)
5. Any other active skin disease associated with chronic itching that might confound the trial evaluations and results in the opinion of the Investigator (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.)
6. History of severe anaphylaxis as defined by Sampson et al. (Section 25.1 ) within 5 years of Screening
7. Any H2 antihistamine, leukotriene receptor antagonist or tricyclic antidepressant use within 3 days prior to Screening
8. Experimental monoclonal antibody therapy (e.g., dupilumab, ligelizumab, etc.) within 6 months or Janus kinase (JAK) inhibitors or experimental Bruton Tyrosine Kinase (BTK) inhibitors within 5 half-lives prior injection of IP
9. Immunosuppressive therapy (e.g., systemic corticosteroids, cyclosporine, methotrexate, dapsone, cyclophosphamide, tacrolimus and mycophenolate mofetil, hydroxychloroquine, etc.) within 4 weeks (or 5 half-lives, whichever is longer) prior to injection of IP
10. ECG findings at Screening that are considered clinically significant
11. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x Upper limit of normal (ULN) at Screening
12. Serum total bilirubin >1.5 x ULN, unless attributable to Gilbert's syndrome
13. Estimated creatinine clearance (eCrCl) by Cockcroft-Gault equation using total body weight < 60 mL/min
14. Known HIV-, hepatitis B-, hepatitis C infection, or acute/long-COVID
15. Major abdominal or thoracic surgery within 8 weeks prior to Screening or planned surgery during trial participation
16. Male participants (who are not vasectomized) who are not willing to use highly effective contraceptive methods (when having sexual intercourse with a female partner of childbearing potential (Section 9.2) and who are not willing to abstain from sperm donation during the trial and for at least 150 days after last IP dosing. A male participant is considered vasectomized if he had a vasectomy at least 4 months prior to Screening and if he has received post-surgical medical assessment of the surgical success of the vasectomy.
17. Female participants of childbearing potential not willing to use highly effective contraceptive methods (Section 9.2) during the trial and for at least 150 days after IP dosing in case of early withdrawal. Women of non-childbearing potential, must be surgically sterile (i.e., had undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or be in menopausal state (at least 1 year without menses).
18. Participation in another research trial involving the use of an IP within the last 30 days (or 5 half-lives of IP, whichever is longer) prior to Screening
19. Any known contraindications or hypersensitivity to any component of IPs, drugs of similar chemical classes (i.e., to murine, chimeric or human antibodies) or antihistamines, leukotrienes
20. Any other acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or IP administration or could interfere with the interpretation of trial results and, in the judgment of the Investigator, would make the participant inappropriate for entry into the trial
21. Participants not willing to abstain from blood donations while being on the trial (Screening to EOT)
22. Close affiliation with the Investigator (e.g., a close relative, financially dependent on the trial site) or participant who is an employee of the Sponsor's company

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Briquilimab; Cohort 1: Participants will be treated at the trial site with 40 mg briquilimab (Subcutaneous Injection) Cohort 2: Participants will be treated at the trial site with 120 mg briquilimab (Subcutaneous Injection) Cohort 3: Participants will be treated at the trial site with 180 mg briqulimab (Subcutaneous Injection)	Drug: Briquilimab; Subcutaneous Injection; Other Names: JSP191

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence and severity of treatment emergent AEs/SAEs [safety and tolerability] of a single dose of briquilimab in patients with ColdU or SD who remain symptomatic despite the use of H1 antihistamines.	Incidence and severity of treatment emergent AEs/SAEs	From signing the informed consent form (ICF) through end of trial (EOT) visit (Week 36)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Preliminary efficacy of briquilimab	Provocation testing: ColdU: Critical temperature threshold (CCT) SD: Critical friction threshold (CFT)	Change from Baseline to all assessment time points through Week 36

Collaborators and Investigators

• Sponsor: Jasper Therapeutics, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 18, 2024
• Primary Completion (Actual): July 31, 2025
• Study Completion (Actual): July 31, 2025

Study Registration Dates

• First Submitted: April 3, 2024
• First Submitted That Met QC Criteria: April 3, 2024
• First Posted (Actual): April 9, 2024

Study Record Updates

• Last Update Posted (Estimated): October 8, 2025
• Last Update Submitted That Met QC Criteria: October 3, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: Immune System Diseases; Itch; Urticaria; Hives; Chronic Urticaria; Skin Diseases; Wheals; Skin Diseases, Vascular
• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Skin Manifestations; Hypersensitivity, Immediate; Hypersensitivity; Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases; Signs and Symptoms; Chronic Urticaria; Chronic Inducible Urticaria; Skin Diseases; Immune System Diseases; Pruritus; Urticaria; Skin Diseases, Vascular
• Other Study ID Numbers: JSP-CP-010; 2023-507534-24 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes